The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70431 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Michael Michael und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Sunitinib, Liver, Kidney Neoplasms, Antineoplastic Agents. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Health and Medical Research Council, Pfizer.
Abstract (Originalsprache)
Aim
Sunitinib has marked pharmacokinetic (PK) and pharmacodynamic (PD) interpatient variability. This study evaluated the utility of extensive excretory/metabolic/PD pharmacogenomics (PGx) with hepatic functional imaging (HNI) to explore their associations with sunitinib PK/PD (toxicity/response) and progression‐free survival (PFS), respectively.
Methods
Eligible patients (pts) suitable for sunitinib therapy. At baseline: (i) PGx: blood analysed by the Affymetrix DMET™ Plus Array (1936 variants/225 genes) and Sanger sequencing (HNF1A, FLT3, VEGFR2, VEGFR3, RET, PDGFRα, TNFα). (ii) HNI: pts given IV 800 MBq 99m Tc‐MIBI, imaging data analysed for hepatic extraction/excretion parameters (CL HNI , T 1/2‐HNI , 1hRET, HEF, T d1/2 ). In cycles 1 and 2, bloods taken for sunitinib parent (SU), metabolite (SU12662) and total SU (metabolite + parent) PK. Associations evaluated between (i) HNI parameters and (2) PGx, with sunitinib PK, toxicity/response and PFS.
Results
N = 15 pts. The two most significant associations in either direction between PGx variants or HNI parameters ( p < .05) for: (i) PK included: (a) SU logAUC 0–14days with HEF, ATP7B (rs1801246) and UGT8 (rs4148254); (b) SU logAUC 0–28days , with T d1/2 , SLC15A1 (rs8187832) and SLC10A2 (rs188096); (c) SU12662 logAUC 0–14days with HEF, ABCC3 (rs11568591), PPARD (rs1003973) and SLC15A1 (rs8187840); and (d) SU12662 logAUC 0–28days with SULT1A2 (rs1059491) and SLC10A2 (rs188096). (ii) Toxicity: (a) Diarrhoea grade 1+ with HEF, VEFGR3 (rs307826) and AKAP9 (rs7785971); (b) ≥grade 3 AEs with CBR1 (rs998383); (iii) overall response rate with SULT1E1 (rs1881668) and GSTA2 (rs2180314); and (iv) PFS with CYP4Z1 (rs4926802) and CYP2A6 (rs28399442).
Conclusions
Exploratory associations were observed between sunitinib PK/PD with hepatic functional imaging with extensive pharmacogenomics. Further validation is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Peninsula and Southeast Oncology, Frankston, Victoria, Australia.
- Biostatistics and Clinical Trial Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
ORCID-Profile: Michael Michael
Förderung
- National Health and Medical Research Council
- Pfizer
Zitieren
APA
Michael, M., Toner, G. C., Ganju, V., Link, E., Thompson, M., Matera, A., Hicks, R. J., Campbell, I., Rowley, S., Karapetis, C. S., Burge, M., & Pook, D. W. (2026). The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70431
Vancouver
Michael M, Toner GC, Ganju V, Link E, Thompson M, Matera A, et al. The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70431
BibTeX
@article{Michael2026,
author = {Michael, Michael and Toner, Guy C and Ganju, Vinod and Link, Emma and Thompson, Mick and Matera, Anetta and Hicks, Rodney J and Campbell, Ian and Rowley, Simone and Karapetis, Christos S and Burge, Matthew and Pook, David W},
title = {The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70431}
}
EUVIMED